​​​​Mission

About Us

SUMMIT is a pan-European research consortium that receives support from the Innovative Medicines Initiative (IMI). It aims at identifying markers that predict the risks of developing diabetes chronic micro- and macro-vascular complications with focus on Diabetic Nephropathy (DN), Diabetic Retinopathy (DR), and Cardiovascular disease (CVD). 

A collection of patient samples from different cohorts has been analyzed by combining a variety of high-throughput techniques encompassing genomics, lipidomics and transcriptomics. Cross-fertilization of the genetic information and biomarker panel with SUMMIT developed imaging methodologies and animal models for diabetes complications, helps determine the association of the discovered markers with the complications. Furthermore, the SUMMIT knowledge integration team, besides aiding in marker discovery also seeks to predict the outcomes and the risk of development of the complications. With such robust methodological, data analysis and clinical expertise, SUMMIT is therefore expected to deliver at the end of the project’s lifetime a set of markers able to better predict disease progression and drug effects, thereby shorten clinical trials.​

To achieve its project goals, SUMMIT draws on the scientific expertise and clinical resources of nineteen leading universities and research institutes, six pharmaceutical companies and one SME (small and medium sized enterprises).

The project started on November 1, 2009.

 

Click here to read more about SUMMIT's major achievements until now

News and Events

SUMMIT SYMPOSIUM
SUMMIT SYMPOSIUM

SUMMIT Symposium at the occasion of the final SUMMIT Plenary meeting! Malmö, 22 April, 2015

press to zoom
5th SUMMIT Newsletter!
5th SUMMIT Newsletter!

This issue informs you about IMI2 and Horizon 2020, it reports on the IMI Diabetes Platform Symposium in Barcelona and has some exciting interviews with SUMMIT partners on their discoveries on plaque imaging and on atherosclerosis. Enjoy the read of the 5th issue of our newsletter

press to zoom
PRESS RELEASE
PRESS RELEASE

SUMMIT, IMIDIA & DIRECT announce the signature of a new Memorandum of Understanding (MoU). The MoU provides the framework for taking collaborative activities between the three public private diabetes partnerships within the Innovative Medicines Initiative (IMI) one step further.

press to zoom
SUMMIT SYMPOSIUM
SUMMIT SYMPOSIUM

SUMMIT Symposium at the occasion of the final SUMMIT Plenary meeting! Malmö, 22 April, 2015

press to zoom
1/3
Zhou2014.jpg
Zhou2014.jpg

press to zoom
Sandholm2014.jpg
Sandholm2014.jpg

press to zoom
Zetterqvist2013.jpg
Zetterqvist2013.jpg

press to zoom
Zhou2014.jpg
Zhou2014.jpg

press to zoom
1/5

Recent Publications

MISSION

To DISCOVER, DEVELOP and QUALIFY potential MARKERS that empower:

  • the identification of patients at high risk of diabetes complications

  • the monitoring of the complications' progression and patients‘ response to therapy 

To use the discovered markers as SURROGATE ENDPOINTS in clinical trials.



Thereby, SHORTEN the long lasting CLINICAL TRIALS to bring about EARLIER availability of NEW THERAPY to diabetic patients.

Related Sites